中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

29 records (took 0.038 seconds)

    유색콩 추출물을 함유하는 조성물
    13.
    发明公开
    유색콩 추출물을 함유하는 조성물 无效
    包含色素提取物的组合物

    公开(公告)号：KR1020160073950A

    公开(公告)日：2016-06-27

    申请号：KR1020160071842

    申请日：2016-06-09

    Applicant: (주)아모레퍼시픽

    Inventor： 김진관 ,  김채욱 ,  정연수 ,  윤준원 ,  임경민 ,  주영협 ,  박영호 ,  신현정

    IPC: A61K36/48 ,  A23L1/30

    CPC classification number: A61K36/48 ,  A23L33/105 ,  A23V2200/30 ,  A23V2200/326

    Abstract: 본발명은유색콩등으로부터추출한유색콩추출물및 그분획물을유효성분으로함유하는항혈전효능조성물에관한것이다. 본발명에의한항혈전조성물은아데노신을포함하고있으며, 혈전형성의원인이되는심장혈관질환, 뇌혈관질환, 동맥경화증, 고혈압, 당뇨등의순환기계질환의치료에매우유용하게이용될수 있다.

    Abstract translation: 本发明涉及抗紫外线组合物，其含有作为活性成分的从有色豆及其部分提取的有色豆提取物。 本发明的抗血栓形成组合物含有腺苷，可用于治疗血栓形成原因的心血管疾病，脑血管疾病，动脉粥样硬化，高血压，糖尿病等循环系统疾病。

    콩 추출물을 함유하는 혈액 순환 개선 및 혈관 건강 증진용 조성물
    18.
    发明公开
    콩 추출물을 함유하는 혈액 순환 개선 및 혈관 건강 증진용 조성물 审中-实审
    包含用于改善血液循环和血管健康的豆提取物的组合物

    公开(公告)号：KR1020100127728A

    公开(公告)日：2010-12-06

    申请号：KR1020100049181

    申请日：2010-05-26

    Applicant: (주)아모레퍼시픽

    Inventor： 신현정 ,  김진관 ,  김채욱 ,  주경미 ,  정연수 ,  임경민 ,  서대방 ,  주영협 ,  이상준 ,  박영호

    IPC: A61K36/48 ,  A23L1/30 ,  A23L2/52

    CPC classification number: A61K36/48 ,  A23L2/52 ,  A23L33/105 ,  A61K2236/333 ,  A23V2200/30

    Abstract: PURPOSE: A composition containing soybean extract isolated with low alcohol is provided to improve blood circulation and to treat obesity, diabetes, and hyperlipidemia. CONSTITUTION: A composition for improving blood circulation contains soybean extract isolating with 1-7% of C1-5 alcohol or fraction. The C1-5 alcohol is methanol, ethanol, isopropylalcohol, n-propylalcohol, n-butanol or isobutanol. The soybean extract or fraction contains adenosine. The fraction is an ethylacetate or butanol fraction. The composition suppresses thrombosis or cholesterol generation.

    Abstract translation: 目的：提供含有用低分子量分离的大豆提取物的组合物，以改善血液循环和治疗肥胖症，糖尿病和高脂血症。 构成：用于改善血液循环的组合物含有用1-7％的C1-5醇或级分分离的大豆提取物。 C 1-5醇是甲醇，乙醇，异丙醇，正丙醇，正丁醇或异丁醇。 大豆提取物或级分含有腺苷。 馏分是乙酸乙酯或丁醇馏分。 该组合物抑制血栓形成或胆固醇的产生。

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    20.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物，其异构体，或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号：KR1020080007329A

    公开(公告)日：2008-01-18

    申请号：KR1020077024002

    申请日：2006-03-15

    Applicant: (주)아모레퍼시픽

    Inventor： 김희두 ,  서영거 ,  박형근 ,  오우택 ,  박설린 ,  김주현 ,  장미정 ,  박영호 ,  신송석 ,  김선영 ,  김진관 ,  정연수 ,  이기화 ,  최진규 ,  임경민 ,  고현주 ,  모주현 ,  김성일 ,  우병영

    IPC: C07C275/24 ,  C07C275/18 ,  A61K31/17

    CPC classification number: C07C275/24 ,  C07C311/08 ,  C07C311/11 ,  C07C323/62 ,  C07D211/46 ,  C07D295/088 ,  C07D295/155 ,  C07D309/12 ,  C07F7/0818

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a pharmaceutical composition effective for preventing or treating pain, migraine, arthralgia, nerve injury, skin diseases, overactive bladder, irritable bowel syndrome, or the like. A compound as a vanilloid receptor antagonist, an isomer or a pharmaceutically acceptable salt thereof is represented by the following formula I. In formula I, X is NHCH2, CR11=CR12, NH, CHR11CHR12 or C=C, wherein each of R11 and R12 represents H, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl or phenyl; R1 is a C2-C5 alkenyl or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl(C1-C3)alkyl, wherein is each phenyl group is non-substituted or substituted with at least one substituent; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5 R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, hydroxy, C2-C5 alkenyloxy, C1-C5 alkoxy(C1-C5)alkoxy, C1-C5 alkoxy(C1-C5)alkoxy(C1-C5)alkyl, C1-C3 alkylpiperazinyl, piperazinyl(C1-C5)alkoxy, piperidinyl(C1-C5)alkoxy, C1-C5 alkoxy (C1-C5)alkylamino, C1-C7 alkylamino, morpholinyl, morpholinyl(C1-C5)alkyloxy, tetrahydropyranyloxy, phenyl or halogen, wherein each phenyl group is non-substituted or substituted with at least one substituent; each of R9 and R10 independently represents H, -SO2R13, -SOR13, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5)alkyl, C2-C5 alkenyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl (C1-C3)alkyl, wherein each phenyl group is non-substituted or substituted with at least one substituent, and R13 is H, amino, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, trifluoromethyl, phenyl or phenyl(C1-C3)alkyl.

    Abstract translation: 提供作为香草素受体拮抗剂的化合物以获得有效预防或治疗疼痛，偏头痛，关节痛，神经损伤，皮肤疾病，膀胱过度活动症，肠易激综合征等的药物组合物。 作为香草酸受体拮抗剂的化合物，其异构体或其药学上可接受的盐由下式I表示。在式I中，X为NHCH 2，CR 11 = CR 12，NH，CHR 11 CHR 12或C = C，其中R 11和R 12 表示H，卤素，C 1 -C 5烷基，C 1 -C 5烷氧基，卤代（C 1 -C 5）烷基或苯基; R1是C2-C5烯基或C2-C5炔基; R2是H，卤素，硝基，氰基，C1-C5烷基，C1-C5烷氧基，卤代（C1-C5）烷基，C2-C5烯基或C2-C5炔基; R2是H，卤素，硝基，氰基，C1-C5烷基，C1-C5烷氧基，卤代（C1-C5）烷基，C2-C5烯基，C2-C5炔基，羧基，C1-C5烷氧羰基，C1-C5烷硫基， 苯基或苯基（C1-C3）烷基，其中每个苯基是未取代的或被至少一个取代基取代; R3是H，C1-C5烷基，C1-C5烷氧基或卤代（C1-C5）烷基; R 4，R 5，R 6，R 7和R 8各自独立地表示H，羧基，C 1 -C 5烷基，硝基，C 2 -C 5烯基，C 1 -C 5烷氧基，C 2 -C 5炔基，卤代（C 1 -C 5）烷基，C 1 -C 5烷硫基 ，C1-C5烷基磺酰基，C1-C5烷基羰基，C1-C5烷氧基羰基，羟基，C2-C5链烯氧基，C1-C5烷氧基（C1-C5）烷氧基，C1-C5烷氧基（C1-C5）烷氧基（C1-C5）烷基 （C1-C5）烷氧基，C1-C5烷氧基（C1-C5）烷基氨基，C1-C7烷基氨基，吗啉基，吗啉基（C1-C5）烷氧基，四氢吡喃基氧基， 苯基或卤素，其中每个苯基未被取代或被至少一个取代基取代; R 9和R 10各自独立地表示H，-SO 2 R 13，-SOR 13，C 1 -C 5烷基，C 1 -C 5烷氧基，卤代（C 1 -C 5）烷基，C 2 -C 5烯基，C 1 -C 5烷氧基羰基，C 1 -C 5烷硫基，苯基或 苯基（C1-C3）烷基，其中每个苯基未被取代或被至少一个取代基取代，R 13是H，氨基，C 1 -C 5烷基，C 2 -C 5烯基，C 1 -C 5烷氧基，卤代（C1- C5）烷基，三氟甲基，苯基或苯基（C1-C3）烷基。

Patent Agency Ranking